International Clinical Trial: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310420) titled 'A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer' on Dec. 16, 2025.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: TerSera Therapeutics LLC

Condition: Advanced Breast Cancer

Intervention: Drug: ZOLADEX

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: December 29, 2025

Target Sample Size: 88

To know more, visit https://clinicaltrials.gov/study/NCT07310420

Dis...